Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hepatology
•
Liver Tumors
How has the GALAD score affected your practice for HCC screening?
Related Questions
How do you approach treatment options for patients with fibrolamellar HCC compared to "normal" HCC?
How does the use of checkpoint inhibitors for treatment of HCC impact timing of liver transplant and subsequent immunosuppression?
How does the identification of a hepatic adenoma in a male patient affect your management and evaluation?
What is your evaluation approach for a new patient referral for an incidentally found liver lesion?
Is there benefit to aggressively treating hemochromatosis in a patient who has already progressed to cirrhosis at the time of diagnosis?
How does managing a patient with concomitant alcohol related liver disease impact your choice of therapies?
In what scenario do you continue surveillance of benign liver tumors, e.g., hepatocellular adenoma, in pregnant patients?
How does a patient who is PNPLA-3 positive (heterozygote or homozygote) impact how you formulate their therapeutic plan?
How do you diagnose cystic fibrosis related liver disease?
How do you utilize Cystatin-C as a marker of renal dysfunction in patients with chronic liver disease?
